Swedbank AB Raises Stock Holdings in Kenvue Inc. $KVUE

Swedbank AB raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 802.9% in the first quarter, Holdings Channel.com reports. The firm owned 4,912,842 shares of the company’s stock after buying an additional 4,368,731 shares during the period. Swedbank AB’s holdings in Kenvue were worth $84,697,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Cornerstone Wealth Group LLC grew its position in shares of Kenvue by 5.9% during the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after buying an additional 606 shares in the last quarter. Physician Wealth Advisors Inc. raised its stake in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Mill Creek Capital Advisors LLC raised its stake in Kenvue by 0.6% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after buying an additional 701 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management lifted its stake in Kenvue by 0.3% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock worth $4,048,000 after purchasing an additional 712 shares during the last quarter. Finally, Philip James Wealth Mangement LLC lifted its position in shares of Kenvue by 5.5% in the 4th quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company’s stock worth $240,000 after buying an additional 726 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on KVUE. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Barclays lowered their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. UBS Group reduced their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Finally, Citigroup lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $19.33.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.59% of the stock is owned by insiders.

Kenvue Stock Performance

Shares of KVUE opened at $19.82 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm’s 50 day moving average is $17.95 and its 200-day moving average is $17.75. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $22.87. The stock has a market capitalization of $38.04 billion, a P/E ratio of 23.31, a P/E/G ratio of 1.48 and a beta of 0.47.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $0.24 earnings per share. Equities research analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is presently 97.65%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.